Methods and compositions for the treatment of head and neck cancer
Disclosed are methods of treating a head and/or neck squamous cell carcinoma in an individual. The method may include the step of administering to an individual a composition comprising an interleukin-1 receptor-associated kinase 1 (IRAK1) inhibitor, which may include inhibitors that inhibit IL-1 receptor-associated kinase 1 in addition to other IL-1 receptor-associated kinases, such as, for example, an IRAK1/4 inhibitor.
1. A method of treating head and/or neck squamous cell carcinoma in an individual, comprising the step of administering to said individual a composition comprising an interleukin-1 receptor-associated kinase 1 (IRAK1) inhibitor, wherein said head and/or neck squamous cell carcinoma is characterized by IRAK1 overexpression in a cell or tissue of said head and/or neck squamous cell carcinoma.
2. The method of claim 1 , wherein said head and/or neck squamous cell carcinoma is characterized by DEK overexpression.
3. The method of claim 1 , wherein said head and/or neck squamous cell carcinoma is human papillomavirus (PV) positive.
4. The method of claim 1 , wherein said head and/or neck squamous cell carcinoma is human papillomavirus (PV) negative.
5. The method of claim 1 wherein said IRAK1 and/or an IRAK1/4 inhibitor is selected from N-acyl-2-aminobenzimidazoles, imidazo[1,2-a]pyridino-pyrimidine, imidazo[1,2-a]pyridino-pyridine, benzimidazolo-pyridine, N-(2-morpholinylethyl)-2-(3-nitrobenzoylamido)-benzimidazole,
LG0250276, or combinations thereof.
6. The method of claim 1 wherein said IRAK1 and/or an IRAK1/4 inhibitor comprises an RNAi sufficient to inhibit IRAK1 expression.
7. The method of claim 1 , wherein said administering step is selected from orally, rectally, nasally, topically, parenterally, subcutaneously, intramuscularly, intravenously, transdermally, or a combination thereof.
8. The method of claim 1 , wherein said administration decreases the growth or metastasis of said head and/or neck squamous cell carcinoma in said individual, as compared to an individual not receiving said composition.
9. The method of claim 1 , wherein said method decreases a marker of viability of head and/or neck squamous cell carcinoma cells.
10. The method of claim 1 , wherein said treatment decreases a marker of viability of head and/or neck squamous cell carcinoma, wherein marker is selected from survival over time, proliferation, growth, migration, formation of colonies, chromatic assembly, DNA binding, RNA metabolism, cell migration, cell adhesion, inflammation, or a combination thereof.
11. The method according to claim 1 , wherein the composition further comprises an inhibitor of DEK.